Business Standard

Caplin Point Lab surges 15% on strong Q4 results

The stock hit a 52-week high of Rs 467 after the company posted 114% growth in profit at Rs 33 cr

Capsules
Premium

Capsules

SI Reporter Mumbai
Caplin Point Laboratories surged 15% to Rs 467, also its 52-week high, on BSE in early morning trade  after the company more than doubled its consolidated net profit at Rs 33 crore in March quarter (Q4FY17), on the back of strong revenue growth. The pharmaceutical company had reported profit of Rs 16 crore in the same quarter a year ago.

Gross revenues during the quarter under review increased by 47% to Rs 121 crore against Rs 82 crore in the corresponding quarter of previous fiscal.

Earnings before interest, tax, depreciation and amortization (EBITDA) margin improved to 40% from

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in